Atomistry » Chlorine » PDB 6uqv-6v4m » 6ut0
Atomistry »
  Chlorine »
    PDB 6uqv-6v4m »
      6ut0 »

Chlorine in PDB 6ut0: Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer

Protein crystallography data

The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0 was solved by G.P.Vigers, D.J.Smith, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 28.32 / 1.94
Space group P 1 21 1
Cell size a, b, c (Å), α, β, γ (°) 74.918, 61.800, 76.050, 90.00, 111.37, 90.00
R / Rfree (%) 17.5 / 22.2

Other elements in 6ut0:

The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer also contains other interesting chemical elements:

Fluorine (F) 4 atoms
Magnesium (Mg) 4 atoms

Chlorine Binding Sites:

The binding sites of Chlorine atom in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer (pdb code 6ut0). This binding sites where shown within 5.0 Angstroms radius around Chlorine atom.
In total 4 binding sites of Chlorine where determined in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0:
Jump to Chlorine binding site number: 1; 2; 3; 4;

Chlorine binding site 1 out of 4 in 6ut0

Go back to Chlorine Binding Sites List in 6ut0
Chlorine binding site 1 out of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 1 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Cl203

b:36.9
occ:1.00
CL1 A:M1X203 0.0 36.9 1.0
C29 A:M1X203 1.7 26.9 1.0
C28 A:M1X203 2.6 25.1 1.0
HD1 A:TYR96 2.8 16.5 1.0
C25 A:M1X203 2.8 24.9 1.0
N9 A:M1X203 2.8 21.9 1.0
HE2 A:MET72 3.1 22.5 1.0
C10 A:M1X203 3.1 19.1 1.0
C20 A:M1X203 3.2 23.6 1.0
HG12 A:VAL9 3.3 15.2 1.0
HE1 A:TYR96 3.4 16.5 1.0
HE3 A:MET72 3.5 22.5 1.0
CD1 A:TYR96 3.6 16.6 1.0
HB A:VAL9 3.6 15.0 1.0
CE A:MET72 3.7 22.2 1.0
C2 A:M1X203 3.7 20.1 1.0
HG22 A:THR58 3.7 14.9 1.0
HG11 A:VAL9 3.8 15.2 1.0
CE1 A:TYR96 3.8 16.0 1.0
HE1 A:MET72 3.9 22.5 1.0
CG1 A:VAL9 3.9 15.3 1.0
C8 A:M1X203 4.0 21.4 1.0
C7 A:M1X203 4.0 19.2 1.0
C27 A:M1X203 4.0 24.6 1.0
C1 A:M1X203 4.1 18.7 1.0
C24 A:M1X203 4.1 26.9 1.0
N41 A:M1X203 4.2 15.6 1.0
CB A:VAL9 4.2 14.9 1.0
HB2 A:GLN99 4.5 18.7 1.0
C26 A:M1X203 4.5 25.1 1.0
N3 A:M1X203 4.5 19.2 1.0
HG3 A:MET72 4.5 23.0 1.0
HA A:TYR96 4.5 17.5 1.0
C21 A:M1X203 4.6 24.5 1.0
HG22 A:VAL9 4.7 14.9 1.0
CG2 A:THR58 4.7 15.2 1.0
HB3 A:TYR96 4.8 17.0 1.0
CG A:TYR96 4.8 16.1 1.0
HB3 A:GLN99 4.8 18.7 1.0
HG13 A:VAL9 4.8 15.2 1.0
HG1 A:THR58 4.8 14.5 0.0
C40 A:M1X203 4.9 16.4 1.0
HG3 A:GLN99 5.0 19.6 1.0

Chlorine binding site 2 out of 4 in 6ut0

Go back to Chlorine Binding Sites List in 6ut0
Chlorine binding site 2 out of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 2 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe atom residue distance (Å) B Occ
B:Cl203

b:25.0
occ:1.00
CL1 B:M1X203 0.0 25.0 1.0
C29 B:M1X203 1.7 17.8 1.0
C28 B:M1X203 2.6 18.3 1.0
HD1 B:TYR96 2.8 16.4 1.0
C25 B:M1X203 2.8 16.4 1.0
N9 B:M1X203 2.9 15.4 1.0
HE2 B:MET72 3.0 20.3 1.0
HE1 B:TYR96 3.2 16.6 1.0
HG12 B:VAL9 3.3 12.5 1.0
C10 B:M1X203 3.3 15.0 1.0
C20 B:M1X203 3.3 16.4 1.0
CD1 B:TYR96 3.5 16.3 1.0
HB B:VAL9 3.5 12.5 1.0
HE3 B:MET72 3.5 20.3 1.0
CE B:MET72 3.7 20.1 1.0
HG22 B:THR58 3.7 13.8 1.0
CE1 B:TYR96 3.7 16.4 1.0
HG11 B:VAL9 3.9 12.5 1.0
C2 B:M1X203 3.9 14.2 1.0
CG1 B:VAL9 3.9 12.6 1.0
C27 B:M1X203 4.0 16.9 1.0
C8 B:M1X203 4.0 13.7 1.0
N41 B:M1X203 4.0 13.4 1.0
C7 B:M1X203 4.0 15.4 1.0
HE1 B:MET72 4.1 20.3 1.0
C24 B:M1X203 4.1 15.1 1.0
C1 B:M1X203 4.2 14.6 1.0
CB B:VAL9 4.2 12.3 1.0
HG3 B:MET72 4.3 20.3 1.0
C26 B:M1X203 4.5 16.1 1.0
HG22 B:VAL9 4.6 12.5 1.0
HB2 B:GLN99 4.6 14.6 1.0
CG2 B:THR58 4.6 14.3 1.0
HG1 B:THR58 4.6 14.2 0.0
HA B:TYR96 4.7 16.8 1.0
C21 B:M1X203 4.7 16.6 1.0
N3 B:M1X203 4.7 15.6 1.0
CG B:TYR96 4.7 16.4 1.0
HG13 B:VAL9 4.8 12.5 1.0
HB3 B:TYR96 4.8 16.8 1.0
C40 B:M1X203 4.9 13.8 1.0
HB3 B:GLN99 4.9 14.6 1.0
CG2 B:VAL9 5.0 12.5 1.0
HG21 B:THR58 5.0 13.8 1.0

Chlorine binding site 3 out of 4 in 6ut0

Go back to Chlorine Binding Sites List in 6ut0
Chlorine binding site 3 out of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 3 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe atom residue distance (Å) B Occ
C:Cl203

b:31.9
occ:1.00
CL1 C:M1X203 0.0 31.9 1.0
C29 C:M1X203 1.7 19.9 1.0
C28 C:M1X203 2.6 17.6 1.0
C25 C:M1X203 2.8 18.3 1.0
HD1 C:TYR96 2.8 13.0 1.0
N9 C:M1X203 2.8 16.4 1.0
HE2 C:MET72 3.0 19.5 1.0
C10 C:M1X203 3.0 15.0 1.0
HG12 C:VAL9 3.2 13.5 1.0
C20 C:M1X203 3.2 17.7 1.0
HE1 C:TYR96 3.3 13.1 1.0
HG11 C:VAL9 3.5 13.5 1.0
HG22 C:THR58 3.6 12.7 1.0
CD1 C:TYR96 3.6 13.2 1.0
C2 C:M1X203 3.7 15.0 1.0
HE3 C:MET72 3.7 19.5 1.0
CE C:MET72 3.7 19.9 1.0
CG1 C:VAL9 3.7 13.9 1.0
HB C:VAL9 3.7 12.7 1.0
CE1 C:TYR96 3.8 12.8 1.0
HE1 C:MET72 3.9 19.5 1.0
C7 C:M1X203 3.9 14.9 1.0
C27 C:M1X203 3.9 16.0 1.0
C8 C:M1X203 4.0 15.8 1.0
C24 C:M1X203 4.0 17.3 1.0
C1 C:M1X203 4.1 15.9 1.0
N41 C:M1X203 4.1 15.0 1.0
CB C:VAL9 4.3 12.8 1.0
HB2 C:GLN99 4.4 14.7 1.0
C26 C:M1X203 4.4 17.4 1.0
HA C:TYR96 4.5 13.7 1.0
CG2 C:THR58 4.5 12.6 1.0
N3 C:M1X203 4.5 14.7 1.0
HG13 C:VAL9 4.6 13.5 1.0
C21 C:M1X203 4.6 16.7 1.0
HG3 C:MET72 4.7 17.5 1.0
HG22 C:VAL9 4.7 12.1 1.0
HG21 C:THR58 4.8 12.7 1.0
HB3 C:GLN99 4.8 14.7 1.0
CG C:TYR96 4.8 12.5 1.0
HG3 C:GLN99 4.8 15.3 1.0
HG1 C:THR58 4.9 12.8 0.0
HB3 C:TYR96 4.9 13.2 1.0
C40 C:M1X203 4.9 14.0 1.0
HG23 C:THR58 4.9 12.7 1.0

Chlorine binding site 4 out of 4 in 6ut0

Go back to Chlorine Binding Sites List in 6ut0
Chlorine binding site 4 out of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 4 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
probe atom residue distance (Å) B Occ
D:Cl203

b:30.5
occ:1.00
CL1 D:M1X203 0.0 30.5 1.0
C29 D:M1X203 1.7 19.9 1.0
C28 D:M1X203 2.6 19.0 1.0
HD1 D:TYR96 2.6 16.6 1.0
C25 D:M1X203 2.8 19.4 1.0
HE3 D:MET72 2.8 21.9 1.0
N9 D:M1X203 3.0 17.1 1.0
HG12 D:VAL9 3.1 16.1 1.0
HE1 D:TYR96 3.2 16.9 1.0
C10 D:M1X203 3.2 15.4 1.0
C20 D:M1X203 3.3 17.1 1.0
CD1 D:TYR96 3.4 16.0 1.0
HB D:VAL9 3.4 16.1 1.0
HE2 D:MET72 3.5 21.9 1.0
CE D:MET72 3.5 21.8 1.0
HG11 D:VAL9 3.6 16.1 1.0
CE1 D:TYR96 3.7 17.2 1.0
CG1 D:VAL9 3.7 15.9 1.0
HG22 D:THR58 3.8 15.3 1.0
C2 D:M1X203 3.8 17.1 1.0
HE1 D:MET72 3.8 21.9 1.0
C27 D:M1X203 4.0 20.5 1.0
C7 D:M1X203 4.0 18.0 1.0
C24 D:M1X203 4.0 18.9 1.0
N41 D:M1X203 4.1 17.2 1.0
CB D:VAL9 4.1 16.5 1.0
C8 D:M1X203 4.2 17.6 1.0
C1 D:M1X203 4.2 17.1 1.0
HG22 D:VAL9 4.4 16.3 1.0
HG3 D:MET72 4.5 18.9 1.0
HA D:TYR96 4.5 16.6 1.0
C26 D:M1X203 4.5 18.2 1.0
HB2 D:GLN99 4.6 16.8 1.0
HG13 D:VAL9 4.6 16.1 1.0
N3 D:M1X203 4.6 16.2 1.0
CG D:TYR96 4.6 16.9 1.0
C21 D:M1X203 4.7 17.7 1.0
HB3 D:TYR96 4.7 16.8 1.0
CG2 D:THR58 4.8 15.3 1.0
HG1 D:THR58 4.8 15.5 0.0
CG2 D:VAL9 4.8 16.3 1.0
C40 D:M1X203 4.8 20.7 1.0
HB3 D:GLN99 4.9 16.8 1.0

Reference:

J.B.Fell, J.P.Fischer, B.R.Baer, J.F.Blake, K.Bouhana, D.M.Briere, K.D.Brown, L.E.Burgess, A.C.Burns, M.R.Burkard, H.Chiang, M.J.Chicarelli, A.W.Cook, J.J.Gaudino, J.Hallin, L.Hanson, D.P.Hartley, E.J.Hicken, G.P.Hingorani, R.J.Hinklin, M.J.Mejia, P.Olson, J.N.Otten, S.P.Rhodes, M.E.Rodriguez, P.Savechenkov, D.J.Smith, N.Sudhakar, F.X.Sullivan, T.P.Tang, G.P.Vigers, L.Wollenberg, J.G.Christensen, M.A.Marx. Identification of the Clinical Development CANDIDATEMRTX849, A Covalent KRASG12CINHIBITOR For the Treatment of Cancer. J.Med.Chem. 2020.
ISSN: ISSN 0022-2623
PubMed: 32250617
DOI: 10.1021/ACS.JMEDCHEM.9B02052
Page generated: Mon Jul 29 15:59:38 2024

Last articles

Zn in 9JPJ
Zn in 9JP7
Zn in 9JPK
Zn in 9JPL
Zn in 9GN6
Zn in 9GN7
Zn in 9GKU
Zn in 9GKW
Zn in 9GKX
Zn in 9GL0
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy